A collection of PD neuropsychiatry experts recently published a thorough review article of anxiety in PD. They note that anxiety consistently ranks among the top 2 or 3 areas of unmet needs identified by people with Parkinson’s. The review discusses what we know—and don’t know—about phenomenology, etiology and treatment. It’s worth a read. Pontone, G.M., […]
The recently published study cited below shows evidence that various measurements of eye function (especially contrast sensitivity and the thickness of the inner plexiform layer in the retina) correlated very strongly with a summary measure of clinical variables associated with dementia risk in people with Parkinson disease (PD). We have long known that the back […]
Lumateperone is a new drug recently approved by the FDA for treatment of schizophrenia. The key clinical trial was just published and includes data on motor side effects of the drug. The sponsor, Intra-Cellular Therapies, Inc., may have data on use in Parkinson disease (PD), but I don’t think any of it is public. So […]
For 5 years, my colleagues and I have written a yearly article reviewing recent key publications related to Tourette syndrome and other tic disorders. The finished “Highlights” articles are published in the Tics collection on the F1000Research platform. That task is getting harder as more and more research is published (see Figure). We are in the process […]
This article about an important detail in treating hallucinations or delusions in Parkinson disease patients was just published. Read all about it here.
Recently someone with TS wrote me to say that he had discovered a trigger for tics and a potential treatment that might apply to others. I applaud his careful observations and willingness to share. But how can we move this observation forward? After all, numerous potential cures to TS have been proposed, ranging from antibiotics […]
The US FDA approved Epidiolex® (cannabidiol, or CBD) for certain seizure syndromes in June, and today the DEA listed it as a Schedule V controlled substance (the least restrictive). This action will greatly facilitate clinical use and clinical trials of CBD in the U.S. Note that there is little evidence at this point that CBD […]
We were happy to participate in the first-ever study of a dopamine D1 blocking drug in children with TS. The study results were recently published, showing evidence of benefit without substantial side effects. Click here for additional background information, a summary of the results, and a link to the publication. (https://goo.gl/gh5YfM)
This web page describes our work, just published, that maps movement-related and non-movement-related effects of deep brain stimulation in Parkinson disease patients.
This web page describes a recent publication from Wash.U. and several other research sites on factors associated with successful tic suppression in 99 children and adolescents with a tic disorder.
A colleague asked me about treatment for tardive dyskinesia and I thought I’d share my answer. Experts have reached different conclusions from the available evidence (e.g., here vs. here). Here is a rough outline as I see it. Make sure it is tardive dyskinesia. You’re looking for involuntary, rhythmic stereotypies at about 0.5-1.0 Hz. They may […]
A recent article from CNN discussed Nuplazid® (pimavanserin), a medication approved by the FDA in 2016 for treatment of hallucinations or delusions in Parkinson’s disease (a.k.a. PDP, for Parkinson disease psychosis). The article made some efforts to present a balanced perspective, but the title and overall tenor of the article focused on the possibility that this new […]
Next time you think you have to give your copyright away to a big-name journal, there are alternatives. Read more here. Sample quote:
Here’s a brief summary of what we know about cannabis and related drugs for treatment of tics.